Early treatment with ceftazidime-avibactam for serious infections
Part of Infections, Lungs & breathing clinical trials.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have symptoms of a bloodstream infection or pneumonia that started in the hospital or from a breathing machine.
- A lab test from your blood or lung mucus found Gram-negative bacteria.
- You are not expected to die within the next 48 hours from shock or other illness.
- Your infection is not linked to a vein catheter that can't be removed.
- Your treatment is aimed at curing the infection, not just comfort care.
- You have not been in this same study in the last 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a precise dosing approach for the antibiotic ceftazidime-avibactam to treat serious infections in ICU patients. It aims to help people with hard-to-treat bacteria that are resistant to many other antibiotics.
This trial tests whether giving the antibiotic ceftazidime-avibactam continuously or intermittently works better for ICU patients with severe infections caused by drug-resistant bacteria. The goal is to see which method improves outcomes.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
This study looks at how well an antibiotic called ceftazidime-avibactam (CAZ-AVI) works in people with blood cancers or those who have had a stem cell transplant. It aims to find the right dose and see if the bacteria become resistant.
This trial tests two ways of giving the antibiotic ceftazidime/avibactam (a powerful drug for resistant bacteria) to critically ill patients in the ICU. The goal is to see if a continuous infusion works better than standard timed doses.
Hear when a new Ventilator Associated Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.